Clinical Trials Browser

Terminated × Myeloproliferative Disorders × Idarubicin × Clear all

NCT04250051 2026-06-01

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute